Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LPL | P06858 | 7/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25358250 | 1.00 | CYP19A1 (0.49) | CYP19A1LMNATDP1CA1CA2 | |
| SCHEMBL24364397 | 0.85 | LMNA (0.58) | CYP19A1LMNATDP1LPLLIPG | |
| SCHEMBL18123774 | 0.84 | CA1 (0.51) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5899727 | 0.84 | LPL (0.65) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5243207 | 0.83 | CA1 (0.61) | CA1CA2CA9LPLLIPG | |
| SCHEMBL16158904 | 0.82 | CA1 (0.47) | CA1CA2CA9LPLLIPG | |
| SCHEMBL29203355 | 0.80 | DGAT1 (0.55) | LPLLIPGDGAT1F11 | |
| SCHEMBL12260751 | 0.80 | LMNA (0.48) | CYP19A1LMNATDP1LTA4HCYP11B1 | |
| SCHEMBL5800988 | 0.78 | CA1 (0.49) | LMNACA1CA2CA9LPL | |
| SCHEMBL16114401 | 0.78 | LMNA (0.75) | CYP19A1LMNATDP1LTA4HCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | CYP19A1 129/4885LMNA 817/4885TDP1 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.